Introduction
============

Low back pain (LBP) has a significant impact on workplace absenteeism of ∼15.5%.[@b1-dddt-10-1987] Mechanical LBP can be secondary to lumbar strain or sprain (70% of all reported cases), age-related degenerative changes (10%), herniated disks (4%), osteoporotic fractures (4%), or spinal stenosis (3%), with all other causes accounting for \<1% of cases. For individuals \<45 years old, mechanical LBP is the most common cause of disability, and it is generally attributed to an acute traumatic event. However, cumulative trauma must also be considered in the etiology, such as occupational overuse injury.[@b2-dddt-10-1987],[@b3-dddt-10-1987]

The best approach to treat LBP appears to be a combination of pharmacological and nonpharmacological strategies.[@b4-dddt-10-1987] There is a great variability, possibly genetically related, in the individual response to painkillers.[@b5-dddt-10-1987] Nonsteroidal anti-inflammatory drugs (NSAIDs) are the most common type of medication used in the treatment of acute pain, exerting their effect by interfering in the inflammatory response.[@b6-dddt-10-1987] They inhibit the cyclooxygenase (COX) enzyme, reducing the synthesis of prostaglandins. The traditional NSAIDs inhibit both COX-1 and COX-2, and inhibiting COX-1 decreases platelet aggregation, irritates the gastric mucosa, and alters renal flow.[@b7-dddt-10-1987]

Ketorolac trometamol (KT; Toragesic^®^, EMS Sigma Pharma Ltd., Campinas, Brazil) is an NSAID, which is a racemic mixture of the S- and R-enantiomeric forms. KT inhibits COX that results in reduced synthesis of prostaglandins, thromboxanes, and prostacyclin as well as diminished platelet aggregation.[@b8-dddt-10-1987] Compared with aspirin, which produces prolonged and irreversible antiplatelet effects that persist beyond drug administration, the anti-platelet activity of KT is not apparent after elimination from the plasma and is reversible. In addition, the platelet effects of KT are not related to dose.[@b8-dddt-10-1987] The S-enantiomer of KT is a rapid-acting and potent analgesic that possesses no anesthetic, sedative, or antianxiety effects and has no effect on gut motility.[@b8-dddt-10-1987] The effectiveness, safety, and analgesic efficacy and potency of KT are considered higher than those of ketoprofen in postoperative ear--nose--throat[@b9-dddt-10-1987] and dental surgeries.[@b10-dddt-10-1987]

The aim of the current clinical trial (protocol number NCT01471886) was to test the hypothesis that KT is not inferior to naproxen (NA) in its analgesic efficacy and incidence of adverse effects for the treatment of moderate-to-severe acute LBP.

Patients and methods
====================

This 10-day, double-dummy, randomized, prospective, noninferiority clinical trial was conducted at two research centers in São Paulo, Brazil, in accordance with the principles of the Declaration of Helsinki and under protocol number 0752/11, which was approved by the Ethics Committee of the University Hospital at São Paulo University.

Because the package insert indicates that the upper limit of use for KT is 5 days, the treatment duration was not longer than 5 days, and the study finished with safety reassessment 10 days after treatment initiation.

Participants
------------

Eighty-three outpatients diagnosed with moderate or severe acute LBP as determined by a visual analog scale (VAS) score \>40 mm were screened. Eligible participants were 18--65 years old and able to give written informed consent. Women of childbearing age had to agree to use contraceptive methods throughout the study. The exclusion criteria included the following: weight \<50 kg; severe congestive heart failure; current alcoholism or illegal drug use; presence of fever or signs of infection; kidney disease; fracture; fibromyalgia; cancer; neuropsychiatric disease; rheumatologic disease; history of peptic ulcer disease, gastrointestinal bleeding, or hemorrhagic diathesis; cerebrovascular disease; hemostatic disorders or use of anticoagulants; pregnancy; lactation; postoperative patients at high risk of bleeding; history of hypersensitivity to any of the ingredients in the formula or other NSAIDs; nasal polyps; and asthma. Participants could not have participated in another experimental study in the 6 months prior to study entry. None of the 83 prospective participants were excluded; thus, these 83 volunteers were randomized.

Treatments, groups, and outcome measures
----------------------------------------

This noninferiority study compared the analgesic efficacy and incidence of adverse effects in the treatment of moderate-to-severe acute LBP for KT at a dosage of 10 mg given sublingually three times daily (TID) and NA at a dosage of 250 mg administered orally TID. Eligible participants were randomly assigned to one of these two treatment groups by a computer-generated lottery. Each participant received a numbered kit in the order of arrival. Both the medical staff and the participants were blinded to the treatment assignments.

A superiority post hoc analysis was performed using a Likert scale. This scale was used to evaluate the investigators' global assessment of efficacy on reducing the participant's pain through the following ratings: excellent, VAS score reduction 50 mm or greater; very good, VAS score reduction between 40 mm and 50 mm; good, VAS reduction between 30 mm and 40 mm; regular, VAS between 20 mm and 30 mm; bad, VAS score 10 mm or less.

During the initial visit (V~0~) on the first treatment day, the participant received two pills of either the tested or reference medication, followed by one tablet every 8 hours, for a total of 40 mg and 1,000 mg, respectively. Thereafter, a daily dosage of 10 mg TID was administered sublingually for the test medication and 250 mg TID for the reference medication. From the second to the fifth day of treatment, if the patient had VAS \>40 mm, increased dosage to four times per day was allowed. Participants were reassessed after the initiation of treatment at 2 days (V~1~) and 4 days (V~2~), when the treatment was discontinued. Ten days (V~3~) after the initiation of the study, participants returned for a safety assessment and adverse events were recorded.

The analgesic effect was evaluated on V~0~ before and 60 minutes after taking the drug (V~0--60~) as well as on V~1~ and V~2~ through a VAS score categorized as follows: 0 mm, no pain; 0.1--40 mm, mild pain; 41--70 mm, moderate pain; and 71--100 mm, severe pain. The primary end point was the rate of pain relief (RPR) calculated by the following formula: $$\text{RPR} = \frac{\text{VAS}_{(\text{vi})} - \text{VAS}_{(\text{vf})}}{\text{VAS}_{(\text{vf})}}$$where VAS~(vi)~ is the VAS on V~0~ (before taking the drug) and VAS~(vf)~ is the VAS on V~0--60~ or V~1~ or V~2~.

The secondary end point was RPR~1~ and was calculated for each of the three drug administrations on each day as follows: $$\text{RPR}_{1} = \frac{\text{VAS}_{(\text{vi})} - \text{VAS}_{(\text{vf})}}{\text{VAS}_{(\text{vf})}}$$where VAS~(vi)~ is the VAS 1 hour before the administration of medication and VAS~(vf)~ is the VAS 1 hour after the administration of medication. Participants were instructed to record adverse events in a diary. The investigators checked the diary on every visit. Adverse effects occurring up to 10 days after V~0~ (V~3~) were also included in the study.

Statistical analysis
--------------------

A sample size of at least 78 participants was deemed sufficient to detect differences in the RPR at a significance level of 5%, power of 80%, noninferiority margin of −10% (as per the recommendation of the US Food and Drug Administration \[FDA\]), and an average difference between 5% and 10%, considering a 20% dropout.[@b11-dddt-10-1987],[@b12-dddt-10-1987] A total of 63 (per protocol) of the 83 (intention-to-treat, ITT) participants completed the study (there was no screening failure). The homogeneity of the demographic and clinical features between the groups was compared by *χ*^2^ tests, Fisher's exact tests (for sex, and clinical changes), Levene's test for variance equality, and *t*-test for two independent samples to compare means between two groups for the averages equality (age, weight, Rolland-Morris, and VAS).

The evaluation of the effectiveness (VAS) was performed by Levene's test for variance equality and *t*-tests for mean equality in the protocol population. The primary end point was the RPR between V~0--60~ and V~0~, between V~1~ and V~0~, and between V~2~ and V~0~. The secondary end point was the pain relief following each of the three drug administrations on each day (RPR~1~). The security assessment was conducted in the ITT population using Levene's test. This population consisted of all participants who received at least one dose of medication.

We also conducted a post hoc superiority analysis. The primary end point for this analysis was the investigators' global assessments of efficacy as measured using a Likert scale. We used a logistic model with a stepwise backward approach to select the dependent variables among treatment, sex, age, current smoking status, alcohol use, and clinical changes (inclusion in the model *P*\<0.05, and exclusion *P*\>0.1). The secondary end point in this analysis was the percentage of participants with improvement in pain relief as assessed by the VAS. For this analysis, we considered pain improvement as VAS scores from 0 to 3 after the administration of medication. We also used a logistic model with a stepwise backward approach to select the dependent variables among treatment, sex, age, current smoking status, alcohol use, and clinical changes (inclusion in the model *P*\<0.05, and exclusion *P*\>0.1).[@b13-dddt-10-1987]

Results
=======

A total of 63 of the 83 participants completed the study. One participant was withdrawn due to adverse effects (acute cholecystitis, improbably associated with the test drug), four due to the use of banned medicine, and five due to a breach of protocol, while four chose to withdraw from the study, and six were withdrawn because of lack of follow-up ([Figure 1](#f1-dddt-10-1987){ref-type="fig"}). Both sample groups were clinically homogeneous, and there was no significant difference between them ([Table 1](#t1-dddt-10-1987){ref-type="table"}).

Comparison of the RPR between V~0~ and V~0--60~ showed a 5.6% gain in the RPR for KT compared with NA, which was below the 10% limit (difference =−0.056; 95% confidence interval \[CI\], −0.166, 0.055) and within the noninferiority margin. Comparing the RPR for V~1~ and V~0~, and for V~2~ and V~0~, the upper limit of the 95% CI was \>10% ([Table 2](#t2-dddt-10-1987){ref-type="table"}). The secondary end point showed that KT was not inferior to NA on day 1 for the first and third administrations of the drug, on day 2 for the second and third administrations, on days 3 and 4 for the first three administrations, and on day 5 for the first and third administrations ([Table 3](#t3-dddt-10-1987){ref-type="table"}).

Because we observed a pattern of superiority in the RPR for KT compared with that for NA ([Figure 2](#f2-dddt-10-1987){ref-type="fig"}), we performed a post hoc analysis using Likert scale scores of the investigators' global assessment of efficacy on reducing the participants' pain as the end point. The final logistic model included age as the only important independent variable after a stepwise approach. On V~1~, participants in the KT group had 193.1% higher odds of pain reduction compared with those in the NA group, controlling for age (95% CI, 1.10--7.80). However, this was not observed on V~2~, at which no statistically significant difference in pain improvement was detected between the two treatment groups ([Table 4](#t4-dddt-10-1987){ref-type="table"}). However, the percentage of participants who reported an improvement in pain relief at V~0--60~ was higher in the KT group (24.2%) than in the NA group (6.5%; *P*=0.049). The percentage of participants rated as excellent, very good, or good by the investigator for the KT treatment group (66.7%) was much higher than that for the NA group (40.0%), with 95% CIs for the differences of −0.493 and −0.041. These results indicated that, compared with the NA treatment, the KT treatment had a margin of superiority equal to 4.1%.

Security assessment
===================

The assessment for adverse effects was performed in the ITT population. There were 35 adverse events in the study population treated with NA and 42 in the population treated with KT. The main adverse effects were diarrhea, stomach pain, drowsiness, nausea, and vomiting. The frequency of occurrence of each event between the two treatments was not statistically significant ([Table 5](#t5-dddt-10-1987){ref-type="table"}). The safety evaluation for changes in the laboratory results performed in the protocol population on V~2~ and V~3~ and compared with that on V~0~ did not show any difference between the two treatment groups ([Table 6](#t6-dddt-10-1987){ref-type="table"}).

Discussion
==========

This study showed that the efficacy of KT was not inferior to that of NA in the treatment of acute LBP of moderate-to-severe intensity, with no significant differences in the occurrence of adverse effects between the two treatment groups. However, participants who received KT exhibited a higher percentage of response after the initial administration and had higher odds of responding according to the investigator's assessment at the first visit, suggesting a faster pain relief in the KT group. The rate of pain relief should always be considered when choosing an analgesic in order to improve the quality of life for patients.

There is evidence that KT is more effective than other NSAIDs in pain reduction from both inflammatory and non-inflammatory etiologies.[@b9-dddt-10-1987],[@b10-dddt-10-1987] Its mechanism of action is to reduce prostaglandin production by blocking COX 1 and 2. It has no sedative or anxiolytic properties.[@b14-dddt-10-1987] The FDA approved ketorolac in November 1989.

In studies of postoperative pain, KT showed an opioid dose-sparing effect and consequently a decrease in the adverse events related to opioids.[@b15-dddt-10-1987],[@b16-dddt-10-1987] In addition, for intravenous administration, KT is more cost-effective than morphine in blunt limb injury.[@b17-dddt-10-1987]

Only two studies have evaluated KT for the treatment of acute LBP, and both studies used opioids as comparators.[@b18-dddt-10-1987],[@b19-dddt-10-1987] In both studies, KT had comparable efficacy and fewer side effects. The current study is the first to compare KT to another NSAID in the management of acute LBP. The treatment of acute LBP is an unmet need in which the variability of medical options, mostly uncontrolled, includes the use of NSAIDs, opioids, corticosteroids, and invasive procedures, such as epidural blockade. The results of our study comparing KT with the gold standard NSAID NA indicated that KT is a valid option for the treatment of LBP.

Conclusion
==========

KT is not inferior to NA in efficacy, provides faster pain relief, and is a safe acute treatment option for acute pain relief.
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![Enrollment and randomization flowchart.\
**Note:** Adverse effect: cholecystitis, improbably associated with the test drug.\
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![Pain relief rate 1 hour after medication.\
**Abbreviation:** NA, naproxen.](dddt-10-1987Fig2){#f2-dddt-10-1987}

###### 

Distribution of demographic data at the beginning of the treatment

  Demographic data                 NA              Ketorolac       *P*-value
  -------------------------------- --------------- --------------- ---------------------------------------------------
  Sex, n (%)                                                       
   F                               19 (46.34)      23 (54.76)      0.51
   M                               22 (53.66)      19 (45.24)      
  Age, years, mean (SD)            45.49 (10.98)   45.60 (9.40)    0.962
  Weight, kg, mean (SD)            78.95 (13.96)   71.61 (10.89)   0.009[a](#tfn1-dddt-10-1987){ref-type="table-fn"}
  Clinical changes, n (%)                                          
   Y                               25 (60.98)      23 (54.76)      0.66
   N                               16 (39.02)      19 (45.24)      
  Concomitant medications, n (%)                                   
   Y                               31 (75.61)      35 (83.33)      0.32
   N                               8 (19.51)       7 (16.67)       
   NoA                             2 (4.88)        0 (0.00)        
  Roland--Morris, mean (SD)                                        
   ITT                             16.02 (5.68)    15.59 (5.37)    0.720
   PP                              16.35 (5.50)    15.50 (5.60)    0.544
  VAS, mean (SD)                                                   
   ITT                             7.68 (1.49)     7.62 (1.43)     0.843
   PP                              7.77 (1.52)     7.58 (1.41)     0.591

**Notes:**

At the beginning of the study, no differences were detected among the groups, except for weight; n, sample.

**Abbreviations:** F, female; ITT, intention to treat; M, male; N, no; NA, naproxen; NoA, no answer; PP, protocol population; SD, standard deviation; VAS, visual analog scale; Y, yes.

###### 

RPR as assessed using VAS scores

  Visits            Parameter   *µ*~2~ (NA)   *µ*~1~ (ketorolac)   *µ*~2~--*µ*~1~   95% CI (LCL)   95% CI (UCL)   Levene's test[a](#tfn3-dddt-10-1987){ref-type="table-fn"} (*P*-value)   *t*-test[b](#tfn4-dddt-10-1987){ref-type="table-fn"} (*P*-value)
  ----------------- ----------- ------------- -------------------- ---------------- -------------- -------------- ----------------------------------------------------------------------- ------------------------------------------------------------------
  V~0--60~ × V~0~   RPR         0.258         0.314                −0.056           −0.166         0.055          0.608                                                                   0.321
  n                 31          33                                                                                                                                                        
  V~1~ × V~0~       RPR         0.387         0.384                0.003            −0.142         0.149          0.882                                                                   0.964
  n                 31          33                                                                                                                                                        
  V~2~ × V~0~       RPR         0.436         0.479                −0.043           −0.218         0.132          0.323                                                                   0.627
  n                 30          33                                                                                                                                                        

**Notes:**

Test for variance equality.

Test for averages equality. *t*-test for two independent samples to compare means between two groups.

**Abbreviations:** CI, confidence interval; NA, naproxen; RPR, rate of pain relief; VAS, visual analog scale; LCL, lower confidence limit; UCL, upper confidence limit.

###### 

Pain relief as assessed by comparing VAS scores 1 hour before and after receiving medication

  Day   Dose          *µ*~2~ (NA; n)   *µ*~1~ (ketorolac; n)   *µ*~2~--*µ*~1~   95% CI (LCL)   95% CI (UCL)   Levene's test[a](#tfn7-dddt-10-1987){ref-type="table-fn"} (*P*-value)   *t*-test[b](#tfn8-dddt-10-1987){ref-type="table-fn"} (*P*-value)
  ----- ------------- ---------------- ----------------------- ---------------- -------------- -------------- ----------------------------------------------------------------------- ------------------------------------------------------------------
  1     1             0.118 (26)       0.168 (28)              −0.050           −0.162         0.061          0.730                                                                   0.370
  2     0.084 (25)    0.127 (28)       −0.042                  −0.200           0.115          0.936          0.589                                                                   
  3     0.084 (22)    0.270 (20)       −0.186                  −0.410           0.038          0.003          0/099                                                                   
  2     1             0.166 (25)       0.173 (29)              −0.007           −0.164         0.151          0.771                                                                   0.933
  2     0.102 (22)    0.176 (27)       −0.075                  −0.233           0.083          0.476          0.339                                                                   
  3     0.144 (22)    0.240 (24)       −0.096                  −0.272           0.079          0.207          0.269                                                                   
  3     1             0.085 (23)       0.179 (27)              −0.094           −0.256         0.067          0.031                                                                   0.243
  2     0.06 (24)     0.227 (24)       −0.168                  −0.289           −0.055         0.000          0.005                                                                   
  3     0.112 (22)    0.250 (20)       −0.139                  −0.324           0.046          0.360          0.141                                                                   
  4     −0.042 (3)    0.232 (11)       −0.274                  −0.778           0.230          0.461          0.128                                                                   
  4     1             0.108 (16)       0.181 (23)              −0.072           −0.229         0.084          0.299                                                                   0.326
  2     0.091 (16)    0.213 (21)       −0.122                  −0.274           0.030          0.115          0.089                                                                   
  3     −0.068 (11)   0.270 (20)       −0.338                  −0.560           −0.117         0.528          0.008                                                                   
  4     0.083 (4)     0.345 (7)        −0.262                  −0.673           0.149          0.289          0.118                                                                   
  5     1             0.038 (10)       0.200 (20)              −0.162           −0.395         0.071          0.034                                                                   0.165
  2     0.115 (8)     0.275 (19)       −0.160                  −0.476           0.155          0.139          0.214                                                                   
  3     0.056 (6)     0.270 (12)       −0.215                  −0.477           0.048          0.035          0.101                                                                   
  4     0.000 (2)     0.131 (4)        −0.131                  −0.524           0.261          0.170          0.258                                                                   

**Notes:** n, number of subjects who received the dose.

Test for variance equality.

Test for equality of means. *t*-test for two independent samples to compare means between two groups.

**Abbreviations:** CI, confidence interval; LCL, lower confidence limit; NA, naproxen; UCL, upper confidence limit; VAS, visual analog scale.

###### 

Efficacy evaluation for investigator ratings of excellent, very good, or good

  Visits      Parameter   Coefficient   SE      *P*-value[a](#tfn10-dddt-10-1987){ref-type="table-fn"}   OR           95% CI OR
  ----------- ----------- ------------- ------- -------------------------------------------------------- ------------ -----------
  V~1~        Age         −0.046        0.026   0.076                                                    0.955        
  Treatment   1.075       0.5           0.031   2.931                                                    1.10--7.80   
  Constant    1.723       1.215         0.156   5.6                                                                   
  V~2~        Age         −0.051        0.025   0.041                                                    0.950        
  Treatment   0.681       0.502         0.210   1.878                                                    0.70--5.03   
  Constant    2.360       1.211         0.051   10.594                                                                

**Note:**

*P*-value for independent variables coefficient by binary logistic regression.

**Abbreviations:** CI, confidence interval; OR, odds ratio; SE, standard error.

###### 

Major adverse effects: incidence as a result of treatment in the ITT population

  Effect                Treatment   
  --------------------- ----------- ---
  Diarrhea              2           2
  Heartburn             6           8
  Dry mouth             0           2
  Nausea                2           1
  Erythematous plaque   1           1
  Drowsiness            6           3
  Vomiting              3           1

**Abbreviations:** NA, naproxen; ITT, intention to treat.

###### 

Percentage of change in laboratory test results for the protocol population on visits 2 (V~2~) and 3 (V~3~) compared with values obtained on the initial visit (V~0~)

  Parameter        Visits          P~1~ (Naprosyn^®^)   P~2~ (Toragesic^®^)   P~1~--P~2~   95% CI (LCL)   95% CI (UCL)   Levene's test[a](#tfn13-dddt-10-1987){ref-type="table-fn"} (*P*-value)   *t*-test[b](#tfn14-dddt-10-1987){ref-type="table-fn"} (*P*-value)
  ---------------- --------------- -------------------- --------------------- ------------ -------------- -------------- ------------------------------------------------------------------------ -------------------------------------------------------------------
  Creatinine       (V~0~ × V~2~)   0.086                0.081                 0.005        −0.127         0.137          0.889                                                                    0.944
  n                35              37                                                                                                                                                             
  AST              (V~0~ × V~2~)   0.029                0.027                 0.002        −0.077         0.080          0.938                                                                    0.969
  n                35              37                                                                                                                                                             
  ALT              (V~0~ × V~2~)   0.000                0.027                 −0.027       −0.082         0.028          0.049                                                                    0.334
  n                35              37                                                                                                                                                             
  Urinalysis                                                                                                                                                                                      
   Urine density   (V~0~ × V~2~)   0.229                0.405                 −0.177       −0.394         0.041          0.002                                                                    0.109
  n                35              37                                                                                                                                                             
   Urine pH        (V~0~ × V~2~)   0.171                0.189                 −0.018       −0.201         0.165          0.700                                                                    0.847
  n                35              37                                                                                                                                                             
   Urine WBC       (V~0~ × V~2~)   0.057                0.027                 0.030        −0.065         0.125          0.206                                                                    0.529
  n                35              37                                                                                                                                                             
   Urine RBC       (V~0~ × V~2~)   0.143                0.108                 0.035        −0.123         0.192          0.380                                                                    0.661
  n                35              37                                                                                                                                                             
   Urine density   (V~0~ × V~3~)   0.314                0.270                 0.044        −0.173         0.261          0.422                                                                    0.686
  n                35              37                                                                                                                                                             
   Urine pH        (V~0~ × V~3~)   0.143                0.189                 −0.046       −0.224         0.131          0.298                                                                    0.604
  n                35              37                                                                                                                                                             
   Urine WBC       (V~0~ × V~3~)   0.086                0.027                 0.059        −0.052         0.169          0.029                                                                    0.284
  n                35              37                                                                                                                                                             
   Urine RBC       (V~0~ × V~3~)   0.057                0.054                 0.003        −0.106         0.112          0.911                                                                    0.955
  n                35              37                                                                                                                                                             

**Notes:**

Test for variance equality.

Test for equality of means. *t*-test for two independent samples to compare means between two groups.

**Abbreviations:** ALT, alanine transaminase; AST, aspartate transaminase; CI, confidence interval; RBC, red blood cells; WBC, white blood cells; P~1~, percentage Naprosyn^®^; P~2~, percentage Toragesic^®^; LCL, lower confidence limit; UCL, upper confidence limit.
